Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Export

@article{Schindl2003, abstract = {PURPOSE: Id (inhibitor of differentiation/DNA binding) -1 is involved in neoangiogenesis, it antagonizes basic helix-loop-helix proteins, inhibits differentiation, and enhances cell proliferation. Aim of this study was to investigate Id-1 protein expression in epithelial ovarian tumors and its clinical relevance in ovarian cancer. EXPERIMENTAL DESIGN: We have investigated Id-1 expression by reverse transcription-PCR and Western blotting in ovarian cancer samples. On the basis of these results, Id-1 protein expression was determined by immunohistochemistry in 101 specimens of epithelial ovarian cancer, in 40 borderline tumors, and in 20 cystadenomas. In these cases, Id-1 expression was correlated with p21 expression, microvessel density, and survival. RESULTS: By immunohistochemistry, detectable expression of Id-1 was found significantly more often in ovarian cancers (74.3\%) than in borderline tumors (32.5\%) and cystadenomas (0\%; P < 0.0001, chi(2) test). Cancer samples with poor or moderate histological differentiation (G3/G2) showed significantly stronger Id-1 expression than cancer samples with high differentiation (G1; P = 0.021, Mann-Whitney test), and no association of Id-1 with p21 expression or microvessel density was found. In cancer samples strong or moderate expression of Id-1 was a strong predictor for shorter overall survival in uni- and multivariate analysis (P = 0.001, Cox-regression). CONCLUSIONS: The level of Id-1 protein expression correlates with the malignant potential of ovarian tumors. In cancer samples, stronger Id-1 expression is associated with poor differentiation and more aggressive behavior of tumor cells, resulting in poor clinical outcome. Consequently, Id-1 inhibition in the future might be of benefit for patients with ovarian cancer.}, address = {Institute of Clinical Pathology, University of Vienna, A-1090 Vienna, Austria.}, author = {Schindl, M. and Schoppmann, S. F. and Str\"{o}bel, T. and Heinzl, H. and Leisser, C. and Horvat, R. and Birner, P.}, citeulike-article-id = {1262475}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/12576450}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=12576450}, issn = {1078-0432}, journal = {Clin Cancer Res}, keywords = {id\_pathway, ovarian\_adeno}, month = {February}, number = {2}, pages = {779--785}, posted-at = {2007-04-28 08:13:26}, priority = {2}, title = {Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/12576450}, volume = {9}, year = {2003} }

TY - JOUR ID - Schindl2003 L3 - citeulike-article-id:1262475 N2 - PURPOSE: Id (inhibitor of differentiation/DNA binding) -1 is involved in neoangiogenesis, it antagonizes basic helix-loop-helix proteins, inhibits differentiation, and enhances cell proliferation. Aim of this study was to investigate Id-1 protein expression in epithelial ovarian tumors and its clinical relevance in ovarian cancer. EXPERIMENTAL DESIGN: We have investigated Id-1 expression by reverse transcription-PCR and Western blotting in ovarian cancer samples. On the basis of these results, Id-1 protein expression was determined by immunohistochemistry in 101 specimens of epithelial ovarian cancer, in 40 borderline tumors, and in 20 cystadenomas. In these cases, Id-1 expression was correlated with p21 expression, microvessel density, and survival. RESULTS: By immunohistochemistry, detectable expression of Id-1 was found significantly more often in ovarian cancers (74.3%) than in borderline tumors (32.5%) and cystadenomas (0%; P < 0.0001, chi(2) test). Cancer samples with poor or moderate histological differentiation (G3/G2) showed significantly stronger Id-1 expression than cancer samples with high differentiation (G1; P = 0.021, Mann-Whitney test), and no association of Id-1 with p21 expression or microvessel density was found. In cancer samples strong or moderate expression of Id-1 was a strong predictor for shorter overall survival in uni- and multivariate analysis (P = 0.001, Cox-regression). CONCLUSIONS: The level of Id-1 protein expression correlates with the malignant potential of ovarian tumors. In cancer samples, stronger Id-1 expression is associated with poor differentiation and more aggressive behavior of tumor cells, resulting in poor clinical outcome. Consequently, Id-1 inhibition in the future might be of benefit for patients with ovarian cancer. IS - 2 JF - Clin Cancer Res SN - 1078-0432 AD - Institute of Clinical Pathology, University of Vienna, A-1090 Vienna, Austria. EP - 785 TI - Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. VL - 9 SP - 779 KW - id_pathway KW - ovarian_adeno AU - Schindl, M AU - Schoppmann, SF AU - Ströbel, T AU - Heinzl, H AU - Leisser, C AU - Horvat, R AU - Birner, P PY - 2003/02// UR - http://view.ncbi.nlm.nih.gov/pubmed/12576450 ER -